Delix is rapidly developing neuroplastogens to help advance the next generation of neurological treatment
Transforming the treatment of neurological conditions
Our diversified pipeline lauds more than 1500 compounds based on more than 10 unique chemical scaffolds that have the potential to treat several neuropsychiatric and neurodegenerative indications.
More than 1 billion people are living with neuropsychiatric conditions
Substance Use Disorders
There is an unmet need for newer, novel treatments
More than 33%
of patients are resistant to current therapies
More than 30 years
since SSRIs were first approved
of patients taking antidepressants have experienced symptom improvement, leaving 80% without relief
Interested in how our technology is pushing the boundaries of neuroscience?